Clinical Trial Update: A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing trametinib plus dabrafenib vs dabrafenib alone in BRAF-mutant melanoma has completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2014-08-15